OsteopetrosisPathogenesis and Rationale for the Use of Interferon-γ-1b

被引:0
|
作者
Lakshmi Shankar
Egbert J. A. Gerritsen
L. Lyndon Key
机构
[1] Medical University of South Carolina,Department of Pediatrics and General Clinical Research Center
[2] Hospital for Sick Children NHS Trust and Institute of Child Health,Department of Immunology
来源
BioDrugs | 1997年 / 7卷
关键词
Bone Resorption; Chronic Granulomatous Disease; Osteopetrosis; Osteoclastic Bone Resorption; Dietary Calcium Intake;
D O I
暂无
中图分类号
学科分类号
摘要
Congenital osteopetrosis is a group of disorders resulting in decreased osteoclastic function and hence decreased bone resorption. Various medical treatments have been attempted to ameliorate the osteopetrotic condition. A calcium-deficient diet has limited further sclerosis in some patients. Prednisone therapy has improved haematological function in some patients, but has not resulted in a reduction in bone mass. Calcitrophic hormones, such as parathyroid hormone (PTH) infusions and oral calcitriol, stimulate osteoclastic activity, and calcitriol in particular has stimulated osteoclastic bone resorption in some patients with osteopetrosis. Bone marrow transplantation, although curative, is limited by paucity of donors, risk of graft-versus-host disease and relapse of the disease.
引用
收藏
页码:23 / 29
页数:6
相关论文
共 50 条
  • [21] Apolipoprotein Alleles and the Response to Interferon-β-1b in Multiple Sclerosis
    Carmona, Olga
    Masuet, Cristina
    Alia, Pedro
    Moral, Ester
    Alonso-Magdalena, Lucia
    Casado, Virginia
    Martin-Ozaeta, Gisela
    Arbizu, Txomin
    EUROPEAN NEUROLOGY, 2011, 65 (03) : 132 - 137
  • [22] Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-α1b:: A second member of the interferon-α family
    Masci, P.
    Olencki, T.
    Wood, L.
    Rybicki, L.
    Jacobs, B.
    Williams, B.
    Faber, P.
    Bukowski, R.
    Tong, K.
    Borden, E. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) : 354 - 361
  • [23] Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs
    MacIntyre, Neil
    Bhardwaj, Sanjay
    Toddywala, Rohinton
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [24] Sustained clinical effectiveness of interferon-β-1b in multiple sclerosis patients
    Shimpi, AV
    Layton, B
    Bashir, K
    ANNALS OF NEUROLOGY, 2004, 56 : S58 - S58
  • [25] Nephrotic syndrome associated with interferon-β-1b therapy for multiple sclerosis
    Kumasaka R.
    Nakamura N.
    Shirato K.
    Fujita T.
    Murakami R.
    Shimada M.
    Nakamura M.
    Osawa H.
    Yamabe H.
    Okumura K.
    Clinical and Experimental Nephrology, 2006, 10 (3) : 222 - 225
  • [26] Interferon-β 1b Augments Pulse Steroid-Associated Hepatoxicity
    Gueltuna, Selcan
    Koeklue, Seyfettin
    Yueksel, Hami
    Basar, Oemer
    Ueskuedar, Oguz
    HEPATITIS MONTHLY, 2008, 8 (04) : 317 - 318
  • [28] Interferon-α1b for the treatment of metastatic melanoma: results of a retrospective study
    Shi, Qiong
    Liu, Lin
    Zhang, Weigang
    Zhao, Yanhong
    Liu, Yu
    Zhu, Guannan
    Guo, Weinan
    Zhao, Tao
    Zhao, Jianhong
    Wang, Lei
    Li, Chunying
    Gao, Tianwen
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1105 - 1110
  • [29] Interferon-γ-1b:: Therapeutic option in advanced idiopathic pulmonary fibrosis?
    Kroegel, C
    Mock, B
    Hengst, U
    Reissig, A
    RESPIRATION, 2004, 71 (06) : 656 - 657
  • [30] Management of interferon-β1b (Betaseron) failures in multiple sclerosis with interferon-αn3 (Alferon N)
    Sheremata, WA
    Minagar, A
    EARLY INDICATORS, EARLY TREATMENTS, NEUROPROTECTION IN MULTIPLE SCLEROSIS, 2003, : 191 - 195